Indication

Mismatch Repair Protein Deficiency

1 clinical trial

2 drugs

Clinical trial

A Phase II Study of Preoperative Pembrolizumab for Mismatch-Repair Deficient and Epstein-Barr Virus Positive Gastric Cancer Followed by Chemotherapy and Chemoradiation With Pembrolizumab

Status: Recruiting, Estimated PCD: 2023-12-31

Drug

Drug